These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29170088)

  • 1. Simplified medical abortion screening: a demonstration project.
    Raymond EG; Tan YL; Comendant R; Sagaidac I; Hodorogea S; Grant M; Sanhueza P; Van Pratt E; Gillespie G; Boraas C; Weaver MA; Platais I; Bousieguez M; Winikoff B
    Contraception; 2018 Apr; 97(4):292-296. PubMed ID: 29170088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mifepristone and misoprostol for early abortion when no gestational sac is present.
    Schaff EA; Fielding SL; Eisinger S; Stadalius L
    Contraception; 2001 May; 63(5):251-4. PubMed ID: 11448464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
    Schaff EA; Eisinger SH; Stadalius LS; Franks P; Gore BZ; Poppema S
    Contraception; 1999 Jan; 59(1):1-6. PubMed ID: 10342079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol.
    Guest J; Chien PF; Thomson MA; Kosseim ML
    BJOG; 2007 Feb; 114(2):207-15. PubMed ID: 17305893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion.
    Dahiya K; Mann S; Nanda S
    Arch Gynecol Obstet; 2011 Jul; 284(1):59-63. PubMed ID: 20652288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation.
    Hamoda H; Ashok PW; Flett GM; Templeton A
    BJOG; 2005 Aug; 112(8):1102-8. PubMed ID: 16045525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac.
    Reeves MF; Kudva A; Creinin MD
    Contraception; 2008 Oct; 78(4):332-5. PubMed ID: 18847584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of a hospital outpatient day procedure for medication abortion at 13-18 weeks gestation: Findings from Nepal
    Blum J; Karki C; Tamang A; Shochet T; Shrestha A; Tuladhar H; Karki A; Sharma J; Abbas DF; Dragoman M; Winikoff B
    Contraception; 2019 Dec; 100(6):451-456. PubMed ID: 31491379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing women's choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually following 200 mg mifepristone.
    Akin A; Dabash R; Dilbaz B; Aktün H; Dursun P; Kiran S; Aksan G; Doğan B; Winikoff B
    Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):169-75. PubMed ID: 19565414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City.
    Peña M; Dzuba IG; Smith PS; Mendoza LJ; Bousiéguez M; Martínez ML; Polanco RR; Villalón AE; Winikoff B
    Int J Gynaecol Obstet; 2014 Oct; 127(1):82-5. PubMed ID: 24957534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss.
    Schreiber CA; Creinin MD; Atrio J; Sonalkar S; Ratcliffe SJ; Barnhart KT
    N Engl J Med; 2018 Jun; 378(23):2161-2170. PubMed ID: 29874535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of efficacy and safety of medical treatment of non-viable first trimester pregnancy].
    Zwierzchowska A; Głuszak M; Jabiry-Zieniewicz Z; Banaszek-Wysoczańska A; Dziadecki W; Barcz E
    Ginekol Pol; 2012 Oct; 83(10):760-5. PubMed ID: 23383562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan.
    Raghavan S; Tsereteli T; Kamilov A; Kurbanbekova D; Yusupov D; Kasimova F; Jymagylova D; Winikoff B
    Eur J Contracept Reprod Health Care; 2013 Apr; 18(2):104-11. PubMed ID: 23387475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of mifepristone and sublingual misoprostol for early medical abortion.
    Lin M; Li YT; Chen FM; Wu SF; Tsai CW; Chen TH; Kuo TC
    Taiwan J Obstet Gynecol; 2006 Dec; 45(4):321-4. PubMed ID: 17175490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation.
    Hamoda H; Ashok PW; Flett GM; Templeton A
    Hum Reprod; 2005 Aug; 20(8):2348-54. PubMed ID: 15878927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
    Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
    Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion.
    Bracken H; Ngoc NT; Schaff E; Coyaji K; Ambardekar S; Westheimer E; Winikoff B
    Obstet Gynecol; 2007 Apr; 109(4):895-901. PubMed ID: 17400851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent use of mifepristone and misoprostol for early medical abortion.
    Li YT; Chen FM; Chen TH; Li SC; Chen ML; Kuo TC
    Taiwan J Obstet Gynecol; 2006 Dec; 45(4):325-8. PubMed ID: 17175491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
    Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
    Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonographic appearance of the uterine cavity following administration of mifepristone and misoprostol for termination of pregnancy.
    Markovitch O; Tepper R; Klein Z; Fishman A; Aviram R
    J Clin Ultrasound; 2006; 34(6):278-82. PubMed ID: 16788959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.